Serum?based microRNA biomarkers for major depression: MiR?16, miR?135a, and miR?1202
39 patients with depression and 36 healthy controls were enrolled. Serum miRNAs gene expression was measured using real?time polymerase chain reaction (PCR) analysis; fnally, the data represent as the 2–?Ct followed by further statistical analysis. Results: Te serum level of miR?16 was signifcantly (P < 0.001) down?regulated (mean: 0.9123 and standard deviation [SD]: 0.06) in compared to normal individuals (mean: 1.6848 and SD: 0.09). Te concentration of miR?135a was also catastrophically decreased (P < 0.001) in the patients (mean: 1.160 and SD: 0.07) in compared to control (mean: 1.819 and SD: 0.09). Te relative miR?1202 expression levels were signifcantly lower (P < 0.001) in the patients (mean: 0.1755 and SD: 0.01) than in the healthy individuals (mean: 0.2939 and SD: 0.01). Te receiver operating characteristic curve analysis indicated the obvious separation between patient and healthy control,
with an AUC of 0.75 (95% confdence interval [CI] = 0.642–0.858, P < 0.001), 0.72 (95% CI = 0.607–0.834, P < 0.001), and 0.74 (95%
CI = 0.630–0.861, P < 0.001) for miR?16, miR?135a, and miR?1202, respectively. Te data suggest that these miRNAs have a potential
to be used as a biomarker of depression with sensitivity 77.8% and specifcity of 61.5% for miR?16, 94.4% and 41.0% for miR?135a as
well as 86.1% and 61.5% for miR?1202, respectively (P < 0.001). Conclusion: Our fndings showed that these miRNA can be used as
a biomarker of depression diagnosis. MiR?135a and miR?1202 exhibited better sensitivity and specifcity, respectively.
This article has been downloaded 90 times up to now.
This work is licensed under a Creative Commons Attribution 3.0 License.